New hope for recurrent endometrial cancer: drug combo shows promise
NCT ID NCT06532539
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with standard chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer without the cancer growing. About 30 participants will receive the treatment and be closely monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact